Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–65.
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.
Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15:269–75.
Chou A, Gonzales JA, Daniels TE, Criswell LA, Shiboski SC, Shiboski CH. Health-related quality of life and depression among participants in the Sjögren’s International Collaborative Clinical Alliance registry. RMD Open. 2017;3(2):e000495.
Clayton JA. Dry eye. N Engl J Med. 2018;378:2212–23.
McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144–67.
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81.
Wang MTM, Muntz A, Mamidi B, Wolffsohn JS, Craig JP. Modifiable lifestyle risk factors for dry eye disease. Cont Lens Anterior Eye. 2021:101409.
Li M, Gong L, Chapin WJ, et al. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012;53:5722–7.
Uchino M, Schaumberg DA. Dry eye disease: Impact on quality of life and vision. Curr Ophthalmol Rep. 2014;1:51–7.
Rolando M, Refojo MF, Kenyon KR. Tear water evaporation and eye surface diseases. Ophthalmologica. 1985;190:147–9.
Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300–6.
Baudouin C, Irkeç M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96(2):111–9.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.
Donthineni PR, Shanbhag SS, Basu S. An evidence-based strategic approach to prevention and treatment of dry eye disease, a modern global epidemic. Healthcare (Basel). 2021;9(1):89.
Barabino S, Aragona P, di Zazzo A, Rolando M, Società Italiana di Dacriologia e Superficie Oculare. Updated definition and classification of dry eye disease: renewed proposals using the nominal group and Delphi techniques. Eur J Ophthalmol. 2021;31(1):42–8.
Pleyer U, Geerling G, Schrader S, Jacobi C, Kimmich F, Messmer E. Wenn Tränenersatzmittel nicht mehr ausreichen: die Bedeutung von Entzündungsprozessen beim Trockenen Auge. Praktische Aspekte einer antientzündlichen Therapie des Trockenen Auges [If Artificial Tears Aren’t Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease]. Klin Monbl Augenheilkd. 2020;237(5):655–68.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–74.
Verjee MA, Brissette AR, Starr CE. Dry eye disease: early recognition with guidance on management and treatment for primary care family physicians. Ophthalmol Ther. 2020;9(4):877–88.
Hessen M. All about osmolarity. Review of Optometry. 2018. https://www.reviewofoptometry.com/article/all-about-osmolarity. Accessed February 2021.
Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642–52.
Garrigue JS, Amrane M, Faure MO, Holopainen JM, Tong L. Relevance of lipid-based products in the management of dry eye disease. J Ocul Pharmacol Ther. 2017;33(9):647–61.
van Setten GB, Baudouin C, Horwath-Winter J, et al. The HYLAN M study: efficacy of 0.15% high molecular weight hyaluronan fluid in the treatment of severe dry eye disease in a multicenter randomized trial. J Clin Med. 2020;9:3536.
Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678–85.
Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125–31.
Leonardi A, Flamion B, Baudouin C. Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocul Immunol Inflamm. 2017;25(4):577-86.
Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–96.
Cook N, Mullins A, Gautam R, Medi S, Prince C, Tyagi N, Kommineni J. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407–20.
Fernández I, López-Miguel A, Enríquez-de-Salamanca A, et al. Response profiles to a controlled adverse desiccating environment based on clinical and tear molecule changes. Ocul Surf. 2019;17(3):502–15.
López-Miguel A, Tesón M, Martín-Montañez V, et al. Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions. Am J Ophthalmol. 2014;157(4):788-798.e2.
Alex A, Edwards A, Hays JD, et al. Factors predicting the ocular surface response to desiccating environmental stress. Invest Ophthalmol Vis Sci. 2013;54(5):3325–32.
Napoli PE, Nioi M, Fossarello M. The, “quarantine dry eye”: the lockdown for coronavirus disease 2019 and its implications for ocular surface health. Risk Manag Healthc Policy. 2021;14:1629–36.
Salinas-Toro D, Cartes C, Segovia C, et al. High frequency of digital eye strain and dry eye disease in teleworkers during the coronavirus disease (2019) pandemic. Int J Occup Saf Ergon. 2021;2021:1–27.
Boccardo L. Self-reported symptoms of mask-associated dry eye: a survey study of 3,605 people. Cont Lens Anterior Eye. 2021;2021:101408.
Pandey SK, Sharma V. Mask-associated dry eye disease and dry eye due to prolonged screen time: are we heading towards a new dry eye epidemic during the COVID-19 era? Indian J Ophthalmol. 2021;69(2):448–9.
Koh S, Rhee MK. COVID-19 and dry eye. Eye Contact Lens. 2021;47(6):317–22.
Rokohl AC, Grajewski RS, Matos PAW, Kopecky A, Heindl LM, Cursiefen C. Ocular involvement in COVID-19: conjunctivitis and more. Klin Monbl Augenheilkd. 2021;238(5):555–60.
Nasiri N, Sharifi H, Bazrafshan A, Noori A, Karamouzian M, Sharifi A. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021;16(1):103–12.
Napoli PE, Nioi M, d’Aloja E, Fossarello M. The ocular surface and the coronavirus disease 2019: does a dual “ocular route” exist? J Clin Med. 2020;9(5):1269.
Robbins T, Hudson S, Ray P, et al. COVID-19: a new digital dawn? Digit Health. 2020;6:2055207620920083.
Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence, measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.
Patel S, Henderson R, Bradley L, Galloway B, Hunter L. Effect of visual display unit use on blink rate and tear stability. Optom Vis Sci. 1991;68(11):888–92.
Spackman W, Waqar S, Booth A. Patient satisfaction with the virtual glaucoma clinic. Eye (Lond). 2020. https://doi.org/10.1038/s41433-020-0946-5.
Scalinci SZ, Trovato BE. Conjunctivitis can be the only presenting sign and symptom of COVID-19. IDCases. 2020;20:e00774.
Almazroa A, Alamri S, Alabdulkader B, Alkozi H, Khan A, Alghamdi W. Ocular transmission and manifestation for coronavirus disease: a systematic review. Int Health. 2021;27:28.
Hu K, Patel J, Swiston C, Patel BC. Ophthalmic manifestations of coronavirus (COVID-19). 2021 May 19. Treasure Island (FL): StatPearls; 2021 Jan. PMID: 32310553.
Dockery DM, Rowe SG, Murphy MA, Krzystolik MG. The ocular manifestations and transmission of COVID-19: recommendations for prevention. J Emerg Med. 2020;59(1):137–40.
Napoli PE, Mangoni L, Gentile P, Braghiroli M, Fossarello M. A panel of broad-spectrum antivirals in topical ophthalmic medications from the drug repurposing approach during and after the coronavirus disease 2019 era. J Clin Med. 2020;9(8):2441.
Shetty R, Lalgudi VG, Khamar P, et al. Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals. Indian J Ophthalmol. 2020;68(7):1349–56.
Napoli PE, Nioi M, d’Aloja E, Fossarello M. Safety recommendations and medical liability in ocular surgery during the COVID-19 pandemic: an unsolved dilemma. J Clin Med. 2020;9(5):1403.
Almazroa A. Sustainability of ophthalmology practice and training during and post the pandemic of coronavirus (COVID-19): a review. Clin Ophthalmol. 2021;15:2355–65.
Wong TY, Bandello F. Academic ophthalmology during and after the COVID-19 pandemic. Ophthalmology. 2020;127(8):e51–2.
Lim LW, Yip LW, Tay HW, et al. Sustainable practice of ophthalmology during COVID-19: challenges and solutions. Graefes Arch Clin Exp Ophthalmol. 2020;258(7):1427–36.
Safadi K, Kruger JM, Chowers I, et al. Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol. 2020;5(1):e000487.
Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefes Arch Clin Exp Ophthalmol. 2020;258(5):1049–55.
Olivia Li JP, Shantha J, Wong TY, et al. Preparedness among ophthalmologists: during and beyond the COVID-19 pandemic. Ophthalmology. 2020;127(5):569–72.
Sadhu S, Agrawal R, Pyare R, et al. COVID-19: limiting the risks for eye care professionals. Ocul Immunol Inflamm. 2020;28(5):714–20.
Romano MR, Montericcio A, Montalbano C, et al. Facing COVID-19 in ophthalmology department. Curr Eye Res. 2020;45(6):653–8.
Ferrara M, Romano V, Steel DH, et al. Reshaping ophthalmology training after COVID-19 pandemic. Eye (Lond). 2020;34(11):2089–97.
de Paiva CS. Effects of aging in dry eye. Int Ophthalmol Clin. 2017;57(2):47–64.
Survey of Health, Age and Retirement in Europe (SHARE). The retirement age rises. Pension reforms in Europe have raised the realized retirement age. http://www.share-project.org/press-news/share-research-findings/new-scientific-findings/the-retirement-age-rises.html. Accessed February 2021.
Golebiowski B, Long J, Harrison K, Lee A, Chidi-Egboka N, Asper L. Smartphone use and effects on tear film, blinking and binocular vision. Curr Eye Res. 2020;45(4):428–34.